Pacific Biomarkers competitors

Milind Deshpande is a President and Chief Executive Officer at ACHILLION PHARMACEUTICALS INC and is based in United States.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Ronald Piervincenzi is a Chief Executive Officer at United States Pharmacopeia and is based in Rockville, Maryland. He has worked as Principal at McKinsey & Company and VP Development Sciences Business Strategy at BIOGEN INC.. Ronald studied at Hofstra University between 1989 and 1993 and Duke University between 1993 and 2000.

Rolf is a dynamic biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development and successful product launch into global markets. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. Rolf developed the strategies for strong patent portfolios to secure innovation that is the bedrock of technology based companies. Rolf is an expert in translating technology into financial concepts and funding presentations to angel investors, early and mid-stage venture firms and late stage private equity firms. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. Rolf stands by the belief that the company success is dependent on a team effort of employees, customers and investors.